Histogenics Insiders
Histogenics employs about 49 people. The company is managed by 14 executives with a total tenure of roughly 116 years, averaging almost 8.0 years of service per executive, having 3.5 employees per reported executive. Break down of Histogenics' management performance can provide insight into the company performance.
| Adam Gridley CEO CEO and President and Director |
| Donald Haut CEO CEO |
Histogenics |
Histogenics Management Team Effectiveness
The company has return on total asset (ROA) of (1.3646) % which means that it has lost $1.3646 on every $100 spent on assets. This is way below average. Histogenics' management efficiency ratios could be used to measure how well Histogenics manages its routine affairs as well as how well it operates its assets and liabilities.Histogenics Workforce Comparison
Histogenics is one of the top stocks in number of employees category among related companies. The total workforce of Biotechnology industry is currently estimated at about 74,492. Histogenics adds roughly 49.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
Histogenics Notable Stakeholders
A Histogenics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Histogenics often face trade-offs trying to please all of them. Histogenics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Histogenics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Adam Gridley | CEO and President and Director | Profile | |
| Donald Haut | CEO | Profile | |
| Garheng Kong | Independent Chairman of the Board | Profile | |
| Jonathan Lieber | CFO | Profile | |
| Stephen Kennedy | CTO | Profile | |
| Michael Lewis | Independent Director | Profile | |
| Daniel Swisher | Director | Profile | |
| Kevin Rakin | Independent Director | Profile | |
| John Johnson | Independent Director | Profile | |
| Joshua Baltzell | Independent Director | Profile | |
| Susan Washer | Director | Profile | |
| David Hood | Director | Profile | |
| David Gill | Independent Director | Profile | |
| Gloria Matthews | Chief Medical Officer | Profile |
Histogenics Workforce Analysis
Traditionally, organizations such as Histogenics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Histogenics within its industry.Histogenics Manpower Efficiency
Return on Histogenics Manpower
| Revenue Per Employee | 531 | |
| Revenue Per Executive | 1.9K | |
| Net Loss Per Employee | 61.6K | |
| Net Loss Per Executive | 215.7K | |
| Working Capital Per Employee | 507.7K | |
| Working Capital Per Executive | 1.8M |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Histogenics information on this page should be used as a complementary analysis to other Histogenics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Histogenics Stock
If you are still planning to invest in Histogenics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Histogenics' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |